Pharming Group N.V. (PHAR)
NASDAQ: PHAR · Real-Time Price · USD
8.68
+0.43 (5.21%)
Oct 29, 2024, 4:00 PM EDT - Market closed
Pharming Group Revenue
Pharming Group had revenue of $74.85M in the quarter ending September 30, 2024, with 12.22% growth. This brings the company's revenue in the last twelve months to $285.75M, up 30.64% year-over-year. In the year 2023, Pharming Group had annual revenue of $245.32M with 19.30% growth.
Revenue (ttm)
$285.75M
Revenue Growth
+30.64%
P/S Ratio
n/a
Revenue / Employee
$748,024
Employees
382
Market Cap
592.04M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 245.32M | 39.69M | 19.30% |
Dec 31, 2022 | 205.62M | 6.75M | 3.39% |
Dec 31, 2021 | 198.87M | -13.30M | -6.27% |
Dec 31, 2020 | 212.17M | 22.79M | 12.03% |
Jan 1, 2020 | 189.39M | 54.26M | 40.15% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Orthofix Medical | 771.65M |
Fulgent Genetics | 290.71M |
Entrada Therapeutics | 239.40M |
Axogen | 173.48M |
Simulations Plus | 70.01M |
Q32 Bio | -12.80M |
PHAR News
- 5 days ago - Pharming Group N.V. (PHAR) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Pharming Group to report third quarter 2024 financial results on October 24 - GlobeNewsWire
- 20 days ago - Pharming Group announces start of Phase II clinical trial of leniolisib for primary immunodeficiencies (PIDs) with immune dysregulation - GlobeNewsWire
- 4 weeks ago - Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib) - GlobeNewsWire
- 2 months ago - Pharming Group to participate in September investor conferences - GlobeNewsWire
- 3 months ago - Pharming Group NV (PHAR) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Pharming Group reports second quarter and first half 2024 financial results and provides business update - GlobeNewsWire
- 3 months ago - Pharming Group to report second quarter and first half 2024 financial results on August 1 - GlobeNewsWire